[{"data":1,"prerenderedAt":93},["ShallowReactive",2],{"news-list":3},[4,38,68],{"id":5,"title":6,"body":7,"date":27,"description":13,"extension":28,"kind":29,"link":30,"meta":31,"navigation":32,"path":33,"seo":34,"stem":35,"summary":36,"__hash__":37},"news\u002Fnews\u002F2025-09-orion-collaboration.md","Abilita announces multi-target collaboration with Orion",{"type":8,"value":9,"toc":23},"minimark",[10,14,17],[11,12,13],"p",{},"Abilita Therapeutics today announced a research collaboration with Orion\nCorporation focused on discovering antibody therapeutics against a series of\nmulti-span GPCR targets. Under the agreement, Abilita applies its EMP™\ndirected-evolution platform to stabilise targets selected by Orion, enabling\ndownstream antibody discovery campaigns.",[11,15,16],{},"The collaboration extends Abilita's track record of partnerships with global\npharma — joining ongoing relationships with Lilly, Amgen, Bristol Myers\nSquibb, GSK, and Regeneron.",[18,19,20],"content-gate",{},[11,21,22],{},"Deal-value language withheld pending client confirmation of public-facing\nfinancial disclosure.",{"title":24,"searchDepth":25,"depth":25,"links":26},"",2,[],"2025-09-04","md","press",null,{},true,"\u002Fnews\u002F2025-09-orion-collaboration",{"title":6,"description":13},"news\u002F2025-09-orion-collaboration","Multi-year discovery collaboration applies Abilita's EMP™ platform to a series of GPCR targets selected by Orion.","64BAY5qDprO9skvoXA4dZJg51RxdlGlgbi3gamZj3Yw",{"id":39,"title":40,"body":41,"date":58,"description":59,"extension":28,"kind":60,"link":61,"meta":62,"navigation":32,"path":63,"seo":64,"stem":65,"summary":66,"__hash__":67},"news\u002Fnews\u002F2025-06-stablyzegraph-publication.md","StabLyzeGraph published in Protein Science",{"type":8,"value":42,"toc":56},[43],[11,44,45,46,50,51,55],{},"A peer-reviewed description of ",[47,48,49],"strong",{},"StabLyzeGraph",", Abilita's internal\ngraph-based predictor for mutations that stabilise multi-span membrane\nproteins, was published in ",[52,53,54],"em",{},"Protein Science",". The tool was co-developed\nwith the Cosconati Lab and is integrated into the EMP™ discovery loop —\nranking candidate variants generated by directed evolution before they\never reach the bench.",{"title":24,"searchDepth":25,"depth":25,"links":57},[],"2025-06-12","A peer-reviewed description of StabLyzeGraph, Abilita's internal\ngraph-based predictor for mutations that stabilise multi-span membrane\nproteins, was published in Protein Science. The tool was co-developed\nwith the Cosconati Lab and is integrated into the EMP™ discovery loop —\nranking candidate variants generated by directed evolution before they\never reach the bench.","publication","https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Fpro.70534",{},"\u002Fnews\u002F2025-06-stablyzegraph-publication",{"title":40,"description":59},"news\u002F2025-06-stablyzegraph-publication","Co-developed with the Cosconati Lab, StabLyzeGraph predicts stabilising mutations from sequence and structural context.","qs8DGk98GFuye-iB2RFDcit50zoxNoCLfAORHidsOt8",{"id":69,"title":70,"body":71,"date":85,"description":86,"extension":28,"kind":60,"link":30,"meta":87,"navigation":32,"path":88,"seo":89,"stem":90,"summary":91,"__hash__":92},"news\u002Fnews\u002F2025-03-gpr75-cryoem.md","GPR75 cryo-EM structure unlocks small-molecule discovery",{"type":8,"value":72,"toc":83},[73,80],[11,74,75,76,79],{},"Abilita's structural biology team determined the first cryo-EM structure of\nthe orphan GPCR ",[47,77,78],{},"GPR75"," in an inactive, EMP-stabilised state. GPR75 has\nbeen validated through human genetics as a target for obesity — loss-of-\nfunction mutations correlate with lower BMI — but historically defied\nstructural characterisation.",[11,81,82],{},"The structure has enabled in-silico screening of multiple small-molecule\nfamilies, with lead candidates expected in 2H 2026.",{"title":24,"searchDepth":25,"depth":25,"links":84},[],"2025-03-18","Abilita's structural biology team determined the first cryo-EM structure of\nthe orphan GPCR GPR75 in an inactive, EMP-stabilised state. GPR75 has\nbeen validated through human genetics as a target for obesity — loss-of-\nfunction mutations correlate with lower BMI — but historically defied\nstructural characterisation.",{},"\u002Fnews\u002F2025-03-gpr75-cryoem",{"title":70,"description":86},"news\u002F2025-03-gpr75-cryoem","First reported cryo-EM structure of an EMP-stabilised GPR75 enables in silico screening of inverse-agonist scaffolds for obesity.","BVrqSapAdcQIqzZ8IfI1YGP4vm-73tqGvL1nAfDQ1AE",1779487983544]